Biomica Ltd., a subsidiary of Evogene Ltd. (EVGN), Thursday announced positive data from its ongoing Phase 1 trial of microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, for the treatment of patients with non-small cell lung cancer or NSCLC, melanoma, or renal cell carcinoma or RCC.
The biotechnology company stated that 55 percent of candidates showed sustained clinical benefit, with notable durations of response of over 16 weeks and with one patient exceeding 80 weeks.
Further, 100 percent of RCC patients and 60 percent of NSCLC patients in the study demonstrated positive clinical outcomes, indicating potential efficacy across different cancer types.
Currently, Evogene's stock is trading at $0.8, up 8.15 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.